|
|
Safety & Watchlist
Reliable picks + red flags
|
|
Safe Pick
|
|
ABTAbbott Labs — 54 Straight Years of Raises and a 6.8% Hike in January
|
After a weekend buried in high-yield spreadsheets, I always like to come back to something you can build a portfolio around. Abbott Labs makes medical devices, diagnostics, nutritional products — they make Ensure and Similac — and established pharmaceuticals. In January 2026, they raised the quarterly dividend to $0.63 per share, up from $0.59. That's a 6.8% bump.
That's 54 consecutive years of dividend increases. Fifty-four. That makes ABT a Dividend King — a company that's raised its payout every single year for at least 50 straight. Only about 50 public companies in America can claim that title.
The yield today is 2.5% — I know, after staring at 14.6% and 18% yields, that looks tiny. But here's why I keep ABT on the safe list: the payout ratio (that's how much of earnings goes to dividends) is well under 50%. Abbott guided for 6.5% to 7.5% sales growth in 2026. There's plenty of room to keep raising. If Abbott keeps hiking at 6–7% per year, your yield on what you paid today doubles in about a decade. Your $10,000 turns into $250 a year right now. But the Abbott of 2036 will be paying you considerably more on that same $10,000. That's the kind of stock that makes a portfolio boring in the best possible way.
|
|
Yield: 2.5%
|
$10K invested = $250/yr
|
Paid: Quarterly
|
|
|
|
Red Flag
|
|
ORCOrchid Island's 21% Yield Is a Trap — Here's What Happened
|
This is the one I need to show you. Orchid Island Capital pays a monthly dividend that currently works out to a 21% annualized yield. On a screener, that number jumps off the page. It's supposed to. That's how yield traps work.
In April 2026, ORC cut its monthly payout from $0.12 to $0.10 per share — a 17% haircut. And this isn't a one-time adjustment; the payout has been trending down for years. The stock sits at $5.71, well below its reported book value of $7.22, which tells you the market doesn't fully trust the assets on the balance sheet.
ORC is a mortgage REIT, like Annaly above, but much smaller and far more concentrated. Its debt-to-equity ratio is close to 8-to-1. That's extreme leverage — think of it like buying an $800,000 house with only $100,000 of your own money. When things go well, returns are amplified. When rates move against you, losses are amplified too.
Here's the lesson: when you see a yield above 15% or 20%, always ask "why is it that high?" Usually, the share price has been falling — and it's falling because the market expects the dividend to get cut again. A 21% yield on a shrinking payout is not 21% income. It's a melting ice cube. The ex-dividend date is September 30, same as NLY's — but the comparison stops there.
|
|
|
|
|
The Extra Yield
This week's calendars, screens & answers
|
|
Weekend headline I loved: PDI dropped below its net asset value for the first time in over a year. When one of PIMCO's flagship income funds goes on sale at a discount, I pay attention — that gap between price ($14.00) and NAV has historically been a buying window.
|
|
Saturday screen results: Ex-dividend dates this Wednesday, September 30 — NLY pays $0.75/share and ORC pays $0.10/share. Both go ex-div the same day. You need to own shares by Tuesday's close to qualify for the payout.
|
|
Someone asked me over the weekend: "What does 'ex-dividend' actually mean?" It's the first day a stock trades without the upcoming dividend attached. If NLY goes ex-dividend Wednesday, you must buy by Tuesday's close. Buy on Wednesday or later, and you wait until next quarter for your first check. Simple deadline — easy to miss.
|
|
|
|
The Dispatch
|
|
I spent the weekend elbow-deep in mortgage REIT filings and closed-end fund data so you didn't have to. Today's lineup: NLY at 14.6% and PDI at 18.9% for the income hunters. Abbott at 2.5% for the long-term compounders. And Orchid Island at 21%? That's the cautionary tale — always check whether earnings cover the dividend before you chase a number on a screener. Tomorrow we shift gears to Dividend Aristocrats and Growth Stars. I've got two names with serious raise streaks in my notes. See you tomorrow.
|
|
— Charlie
|
|
|
|